

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2007; month=12; day=4; hr=13; min=57; sec=54; ms=828;]

=====

Application No: 10557583 Version No: 1.0

Input Set:

Output Set:

Started: 2007-11-14 15:54:46.973
Finished: 2007-11-14 15:54:47.974
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 1 ms
Total Warnings: 12
Total Errors: 2
No. of SeqIDs Defined: 12
Actual SeqID Count: 12

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

SEQUENCE LISTING

<110> DE ROUGE, BONABES
MABROUK, KAMEL
SABATIER, JEN-MARC

<120> MODIFIED ANTIVIRAL PEPTIDES WITH INCREASED ACTIVITY AND
CELL MEMBRANE AFFINITY

<130> 20647/0203621-US0

<140> 10557583

<141> 2007-11-14

<150> PCT/EP04/005563

<151> 2004-05-20

<150> GB 0311565.6

<151> 2003-05-20

<150> GB 0319514.6

<151> 2003-08-20

<160> 12

<170> PatentIn Ver. 3.3

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 1

Gly Pro Gly Arg

1

<210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2

Ile Gly Pro Gly Arg

1

5

<210> 3

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (2)..(3)
<223> variable amino acid

<400> 3
Ile Xaa Xaa Gly Pro Gly Arg
1 5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 4
Gly Pro Gly Arg Ala Phe
1 5

<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (8)
<223> beta-Ala

<400> 5
Lys Lys Lys Lys Lys Lys Ala
1 5

<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 6

Arg Gln Gly Tyr

1

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 7

Arg Gln Gly Tyr Ser Pro Leu

1

5

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 8

Arg Gln Gly Tyr Ser Pro

1

5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 9

Arg Gln Gly Tyr Ser

1

5

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

peptide

<400> 10

Gly Arg Gly Arg Ala
1 5

<210> 11

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 11

Lys Lys Lys Lys Lys Lys Lys
1 5

<210> 12

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 12

Gly Pro Gly Arg Ala
1 5